All News
The RheumNow Week in Review – 20 January 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.
Read ArticleConsensus Guidelines for Juvenile Dermatomyositis Management
SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) was established in 2012 to optimise the diagnosis and treatment of several pediatric diseases. They have recently published their recommendations regarding the diagnosis and management of juvenile dermatomyositis (JDM).
Read ArticleDietary Intake Triggers Inflammation
IL-1β, along with pancreatic insulin, helps regulate blood sugar levels, as well as chronic inflammation.
Read ArticleRituximab Effects on ANCA, IgG and Infectious Risk in ANCA-Associated Vasculitis
Rituximab has significantly changed the management of patiehts with ANCA-associated vasculitis (AAV). Yet the longitudinal assessment of such patients needs to be guideded by clinical and laboratory parameters.
Read ArticleThe RheumNow Week in Review – 13 January 2017
Dr. Jack Cush reviews highlights from this past week on RheumNow.com:
Read ArticleStatins Don't Increase Risk of Colchicine Myopathy
Neuromyopathy is a rare side effect of chronic colchicine use. Statins are more commonly implicated as a cause of drug-induced myopathy.
Given the frequent occurrence of the metabolic syndrome, simultaneous use of both colchicine and statins is common.
Read ArticleTREG Innovators Win the Crafoord Prize
The 2017 Crafoord Prize from the Royal Swedish Academy of Sciences has been awarded to a Japanese scientists and two American scientists for their discovery and research on T regulatory cells (TRegs).
Read ArticleMultiple Comorbidity Risks with Giant Cell Arteritis
Elderly patients treated with high doses of corticosteroids are bound to have multiple medical problems. But this was only recently quantified by researchers analyzing a a population-based cohort of biopsy-proven giant cell arteritis (GCA) patients in Southern Sweden.
Read ArticleThe RheumNow Week in Review – 6 January 2017
Dr. Jack Cush reviews highlights from the first week of 2017 on RheumNow.com.
Happy New Year!
Read ArticleBiopsy Proven Renal Involvement in Sjogren's Syndrome
A French multicenter study of primary Sjogren's syndrome (pSS) patients fulfilling the American–European Consensus Group criteria or enlarged American–European Consensus Group criteria were retrospectively studied based on having biopsy-proven renal involvement.
Read ArticleDMARDs Under Study for Secondary Prevention of Cardiovascular Events
Several important lines of population and large cohort research have shown that rheumatoid arthritis (RA) patients have a substantially higher risk for myocardial infarction and major cardiovascular events.
Read ArticleRheumNow Week in Review – 16 December 2016
Dr. Jack Cush reviews highlights from this week on RheumNow.com
Read ArticleEULAR 2016 Recommendations on Early Arthritis
Combe and leading European rheumatologist have published an update to the 2007 European League Against Rheumatism (EULAR) recommendations for management of early arthritis.
Read ArticleLupus May Be at Increased Risk for Dementia
Neuropsychiatric manifestations of systemic lupus erythematosus (SLE) may occur in up to half of patients in their lifetime.
However, dementia is often not reported or studied in cohorts with neurologic disease in lupus.
Read ArticleRandom Drug Levels and Anti-Drug Antibodies Predict Rheumatoid Outcomes
Researchers from Manchester, UK have reported the results of their BRAGGSS study showing that certolizumab (CZP) random drug levels and anti-drug antibody (ADAbs) levels can predict optimal outcomes in CZP treated rheumatoid arthritis patients.
Read ArticleThe RheumNow Week in Review – 2 December 2016
Dr. Cush highlights reports from this week on RheumNow.com.
Read ArticleDiffuse Cutaneous Systemic Sclerosis: Results of the SCOT Trial
Diffuse cutaneous systemic sclerosis (dcSSc) is one of the most difficult autoimmune diseases to treat. In case of major organ involvement (lung, kidney), prognosis is poor and treatment options are limited.
Read ArticleUstekinumab Effective and Safe in Crohn's Colitis
The New England Journal of Medicine has reported the results of a large clinical trial demonstrating the efficacy of ustekinumab (Stelara) in treating patients with active Crohn's disease (CD). (Citation source http://buff.ly/2gsSNcs)
Read ArticleMaintenance of Remission in ANCA-vasculitis: MAINRITSAN study.
It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.
Read Article


